Xintela AB (publ) (OM: XINT)
Health Care · Biotechnology · SE
Skr0.16
-10.31% today · -62.2% 1Y
Xintela AB (publ) (OM: XINT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.00M and employs 11 people.
Over the last twelve months the share price has lost 62.2%, trading between 0.14 and 0.48.
Tweenvest scores Xintela AB (publ) across four factors: quality 23/100, value 62/100. Its strongest factor is value.
XINT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.00M
- Revenue (TTM)
- $312.52K
- P/E
- —
- EPS
- -0.07
- Dividend yield
- —
- Beta (5Y)
- 1.91
- 52-week high
- Skr0.48
- 52-week low
- Skr0.14
- Avg volume (3M)
- —
- Shares outstanding
- 861.27M
- Employees
- 11
- Next earnings
- —
About Xintela AB (publ)
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
- ISIN
- SE0007756903
- Founded
- 2009
- Listed since
- Mar 22, 2016
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aptamer Group PLCAIM: APTA | $14.29M | £0.00 | -4.62% |
| Allarity Therapeutics, Inc.NasdaqCM: ALLR | $14.24M | $0.90 | -9.60% |
| Abera Bioscience ABNGM: ABERA | $14.09M | Skr— | — |
| Pasithea Therapeutics Corp.NasdaqCM: KTTA | $14.03M | $0.42 | -10.16% |
| BioCardia, Inc.NasdaqCM: BCDA | $13.93M | $0.92 | -11.53% |
| Biophytis S.A.ENXTPA: ALBPS | $13.57M | €0.03 | +8.81% |
| Genflow Biosciences plcLSE: GENF | $13.22M | £0.02 | -1.41% |
| Alzinova AB (publ)OM: ALZ | $13.21M | Skr0.43 | -1.96% |
Figures last refreshed Oct 18, 2026.